Table 1.
Ovarian cancer clinical data. A predominance of ovarian serous cystadenocarcinoma with malignant ascites can be observed. Cytoreduction was optimal in 14 patients and suboptimal in 10 patients: only 10 patients were platinum-sensitive, 4 platinum-resistant, and 7 platinum-refractory (all 7 perished during the first year). The majority of patients were discovered in advanced stages.
| Platinum-sensitive | Platinum-resistant | Platinum-refractory | |
|---|---|---|---|
| Weight (kg) | 69 ± 19 | 75 ± 25 | 46 ± 21 |
| Body mass index (BMI) | 27 ± 7 | 30 ± 9 | 21 ± 4 |
| Ag CA-125 baseline U/mL | 607.37 ± 183.13 | 915.8 ± 373.87 | 963 ± 363.80 |
| Ag CA-125 final U/mL | 21.87 ± 6.59 | 4211.95 ± 2105.98 | 62.6 ± 25.56 |
| Clinical stage | |||
| IC | 2 | ||
| IIB | 2 | ||
| IIIB | 2 | 1 | |
| IIIC | 4 | 2 | 5 |
| IV | 1 | 2 | |
| Histology | 9 Cystadenocarcinoma | 3 Cystadenocarcinoma | 6 Cystadenocarcinoma |
| 1 Undifferentiated | 1 Endometrioid type | 1 Endometrioid type | |
| Ascites | 3 Positive | ||
| Malignant ascites | 7 Positive | 4 Positive | 7 Positive |
| Cytoreduction | 10 Optimal | 3 Suboptimal 1 Optimal |
7 Suboptimal |
| Cycle frequency days | 21 | 21 | 5–1 cycle |
| 1–6 cycles | |||
| 1-2 cycles | |||
| Carboplatin (mg) | 570 ± 109 | 471 ± 187 | 464 ± 124 |
| Paclitaxel (mg) | 300 ± 39 | 273 ± 106 | 254 ± 63 |
| Deceased | 2 | 7 |